Cargando…

Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition

Immune checkpoint blockade has shown significant clinical benefit in multiple cancer indications, but many patients are either refractory or become resistant to the treatment over time. HER2/neu oncogene overexpressed in invasive breast cancer patients associates with more aggressive diseases and po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Chang-ling, Zhu, Hai-xia, Deng, Lan, Meng, Xiao-qing, Li, Kai, Xu, Wei, Zhao, Le, Liu, Yue-qin, Zhu, Zhen-ping, Huang, Hao-min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888617/ https://www.ncbi.nlm.nih.gov/pubmed/33990766 http://dx.doi.org/10.1038/s41401-021-00683-8

Ejemplares similares

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
por: Chen, Yi-Li, et al.
Publicado: (2021)

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
por: Li, Li, et al.
Publicado: (2020)

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
por: Suh, Koung Jin, et al.
Publicado: (2017)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade
por: Rossi, Alessandra, et al.
Publicado: (2020)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
por: Lin, Wu, et al.
Publicado: (2023)

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer
por: Yun, Tian, et al.
Publicado: (2020)

Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
por: Karabajakian, Andy, et al.
Publicado: (2020)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids
por: Chakrabarti, Jayati, et al.
Publicado: (2021)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
por: Karabajakian, Andy, et al.
Publicado: (2022)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism
por: Liu, Xingluo, et al.
Publicado: (2003)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
por: Caldwell, Charles, et al.
Publicado: (2017)

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
por: Xue, Gang, et al.
Publicado: (2019)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2020)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
por: Nascimento, Catarina, et al.
Publicado: (2020)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis (Adv. Sci. 30/2023)
por: Lin, Wu, et al.
Publicado: (2023)

Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells
por: Murayama, Masanori A., et al.
Publicado: (2022)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
por: Chen, Kaiyan, et al.
Publicado: (2020)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2021)

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
por: Padmanabhan, Regina, et al.
Publicado: (2020)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
por: D’Amico, Lucia, et al.
Publicado: (2019)

Impaired in vitro Interferon-γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation
por: Takele, Yegnasew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tkp54v3f2hpl7othcqmb1mgtog